# Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

> **NCT04261777** · PHASE3 · TERMINATED · sponsor: **Saving Patients' Lives Medical B.V.** · enrollment: 172 (actual)

## Conditions studied

- Prostate Cancer
- Metastasis
- Prostatectomy

## Interventions

- **DRUG:** Ferrotran® (Ferumoxtran-10)

## Key facts

- **NCT ID:** NCT04261777
- **Lead sponsor:** Saving Patients' Lives Medical B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-27
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 172 (ACTUAL)
- **Why stopped:** The study was closed prematurely in order to finalise it under EU directive 2001/20/EC, without transitioning to EU-CTR, and avoiding unnecessary delay of the marketing authorisation application.
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04261777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04261777, "Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04261777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*